The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives

  title={The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives},
  author={Onder Tonyali and Çağatay Arslan and Kadri Altundag},
  journal={Expert Opinion on Pharmacotherapy},
  pages={2715 - 2725}
Importance of the field: Breast cancer is one of the leading causes of cancer-related deaths in the world. Despite the significant improvements in the adjuvant treatment strategies of early-stage breast cancer, many patients experience relapse. Bisphosphonates are widely used in the treatment of bone metastasis of solid tumors and multiple myeloma, as well as in osteoporosis. The results of clinical studies of adjuvant treatment on early-stage hormone-receptor-positive breast-cancer patients… Expand
Gingival squamous cell carcinoma induced by zoledronic acid treatmentof breast cancer with brain metastasis : a case report and review of the literature
Zoledronic acid is prescribed to reduce bone resorption and improve bone remodeling and has recently been used to treat breast cancer. A female patient had bone-metastatic breast cancer complicatedExpand
Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit
Bisphosphonates switch therapy should be preferred in those with progressive bone metastasis since it might contribute to better survival despite bisph phosphonates could not have been shown to have survival benefit in previous studies. Expand
Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice.
It is confirmed that depression induced bone metastasis by promoting osteoclast activity while inhibiting osteoblast differentiation and activating RUNX2 in breast cancer cells, suggesting that the suppression of gut‑derived serotonin decreases the rate of breast cancerBone metastasis induced by depression. Expand
Bisphosphonates: Focus on Inflammation and Bone Loss
An update on the use of bisphosphonates is given, outlining the possible side effects and proposing new trends for the future, to be able to maximize their properties concerning modulation of inflammation and bone remodelling. Expand
L-α-lysophosphatidylinositol meets GPR55: a deadly relationship.
  • R. Ross
  • Biology, Medicine
  • Trends in pharmacological sciences
  • 2011
It is revealed that LPI activates GPR55, a G protein-coupled receptor that couples to G(12/13) and G(q) proteins, which direct oncogenic signalling and are key partners in driving cancer cell proliferation and migration. Expand
GPR55: a new promising target for metabolism?
The role of GPR55 in energy balance and glucose metabolism, and its actions on feeding, nutrient partitioning, gastrointestinal motility and insulin secretion in preclinical models and the scarce data available in humans are reviewed. Expand
Pharmacology: MRONJ risk factor
I am pleased to be able to reassure Dr Lawrence that the BDJ will not be marking the Summer Solstice or any other seasonal celebrations in a similar manner so he may read the rest of the 2018 issues with unguarded belief. Expand
No studies
I am pleased to be able to reassure Dr Lawrence that the BDJ will not be marking the Summer Solstice or any other seasonal celebrations in a similar manner so he may read the rest of the 2018 issues with unguarded belief. Expand


Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.
Bisphosphonates are potent inhibitors of bone osteolysis and their use in early-stage cancer could be an adjuvant therapeutic strategy of potential importance, according to well-recognized release of bone cell-activating factors from the tumor. Expand
Pamidronate as adjuvant treatment for prevention of bone metastasis in breast cancer
The efficacy of adjuvant pamidronate therapy for prevention of bone metastasis in women with breast cancer and its role in reducing tumor-associated skeletal complications is evaluated. Expand
Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Clodronate can reduce the incidence and number of new bony and visceral metastases in women with breast cancer who are at high risk for distant metastases. Expand
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel
It is suggested that, in addition to inhibiting bone resorption, zoledronic acid has a direct anti-tumour activity on breast cancer cells in vitro and the commonly used anti-neoplastic agent, paclitaxel, potentiates the anti-Tumour effects of zoledronics acid. Expand
Exploring the anti-tumour activity of bisphosphonates in early breast cancer.
The potential synergistic anti-tumour effects of the sequential treatment of neoadjuvant chemotherapy followed by zoledronic acid in a randomised phase II study evaluating biological endpoints including apoptosis, proliferation and angiogenesis in patients with breast cancer is explored. Expand
Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients.
In this first prospective, randomized, multicenter trial, it is shown that both treatment groups have a reduction in the number of DTC after 12 months as compared to baseline, and there is a tendency to more reduction of D TC in the ZOL group. Expand
[Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].
These results indicate a potential antineoplastic effect of zoledronate, a cell-cycle independent drug, on persisting ITC in a dormant state in patients with breast cancer after they had completed primary therapy. Expand
Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer
The results suggest that oral UFT is an effective chemotherapeutic agent for advanced breast cancer accompanying bone metastases and that the combination with BP increases its benefits forBone metastases. Expand
Mechanisms of the Synergistic Interaction between the Bisphosphonate Zoledronic Acid and the Chemotherapy Agent Paclitaxel in Breast Cancer Cells in vitro
It is found that the sequential treatment is associated with cell cycle changes and depends on breast cancer cell characteristics, with hormone independence, mutated p53 status and presence of BRCA1 gene being associated with higher levels of apoptosis. Expand
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
Zoledronic acid administered with chemotherapy resulted in a decreased proportion of patients with DTCs detected in the bone marrow at the time of surgery, which supports the hypothesis that the antimetastatic effects of zoledronic Acid may be through effects on D TCs. Expand